GB9002016D0 - Hmg coa reductase inhibitor and method for lowering serum cholesterol - Google Patents

Hmg coa reductase inhibitor and method for lowering serum cholesterol

Info

Publication number
GB9002016D0
GB9002016D0 GB909002016A GB9002016A GB9002016D0 GB 9002016 D0 GB9002016 D0 GB 9002016D0 GB 909002016 A GB909002016 A GB 909002016A GB 9002016 A GB9002016 A GB 9002016A GB 9002016 D0 GB9002016 D0 GB 9002016D0
Authority
GB
United Kingdom
Prior art keywords
coa reductase
reductase inhibitor
serum cholesterol
hmg coa
lowering serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB909002016A
Other versions
GB2227662B (en
GB2227662A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ER Squibb and Sons LLC filed Critical ER Squibb and Sons LLC
Publication of GB9002016D0 publication Critical patent/GB9002016D0/en
Publication of GB2227662A publication Critical patent/GB2227662A/en
Application granted granted Critical
Publication of GB2227662B publication Critical patent/GB2227662B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
GB9002016A 1989-02-01 1990-01-30 Lowering serum cholesterol using a hmg coa reductase inhibitor and a squaline synthetase inhibitor Expired - Fee Related GB2227662B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30534389A 1989-02-01 1989-02-01

Publications (3)

Publication Number Publication Date
GB9002016D0 true GB9002016D0 (en) 1990-03-28
GB2227662A GB2227662A (en) 1990-08-08
GB2227662B GB2227662B (en) 1993-03-17

Family

ID=23180410

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9002016A Expired - Fee Related GB2227662B (en) 1989-02-01 1990-01-30 Lowering serum cholesterol using a hmg coa reductase inhibitor and a squaline synthetase inhibitor

Country Status (6)

Country Link
JP (1) JPH02235821A (en)
CA (1) CA2007643A1 (en)
DE (1) DE4002836C2 (en)
FR (1) FR2642311B1 (en)
GB (1) GB2227662B (en)
IT (1) IT1238080B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05239075A (en) * 1991-08-27 1993-09-17 Eisai Co Ltd Phosphorus-containing isoprenoid derivative
JP3526575B2 (en) 1993-03-08 2004-05-17 エーザイ株式会社 Phosphonic acid derivatives
AU4988100A (en) * 1999-05-07 2000-11-21 Brigham And Women's Hospital Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
DE10038043B4 (en) * 2000-08-02 2006-09-07 Walter, Michael, Dr. Phamacologically active substance for the treatment of cardiovascular diseases
AUPR549901A0 (en) 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
BR0211673A (en) 2001-07-27 2004-07-13 Vital Health Sciences Pty Ltd Dermal therapy using phosphate derivatives of electron transfer agents
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
AU2003901812A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphates of secondary alcohols
WO2005084678A1 (en) 2004-03-03 2005-09-15 Vital Health Sciences Pty Ltd Alkaloid formulations
AR054368A1 (en) * 2005-06-01 2007-06-20 Takeda Pharmaceutical METHOD TO TREAT HYPERLIPIDEMIA
KR20080019228A (en) 2005-06-17 2008-03-03 바이탈 헬스 사이언시즈 피티와이 리미티드 A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
AU2011213557B2 (en) 2010-02-05 2015-05-07 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
CN102821791B (en) 2010-03-30 2015-06-17 磷肌酸有限公司 Transdermal delivery patch
EP2685992A4 (en) 2011-03-15 2014-09-10 Phosphagenics Ltd Amino-quinolines as kinase inhibitors
CA3007587C (en) 2015-12-09 2023-12-05 Phosphagenics Limited Pharmaceutical formulation
BR112019012946A2 (en) 2016-12-21 2019-11-26 Avecho Biotechnology Ltd process

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2009918A6 (en) * 1987-05-22 1989-10-16 Squibb & Sons Inc Phosphorus-containing HMG-CoA reductase inhibitors
US4871721A (en) * 1988-01-11 1989-10-03 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors
CA2003478A1 (en) * 1988-12-12 1990-06-12 Leonard G. Dennick Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination

Also Published As

Publication number Publication date
IT9019220A0 (en) 1990-02-01
IT9019220A1 (en) 1990-08-02
FR2642311B1 (en) 1991-10-25
JPH02235821A (en) 1990-09-18
IT1238080B (en) 1993-07-05
DE4002836A1 (en) 1990-08-02
GB2227662B (en) 1993-03-17
CA2007643A1 (en) 1990-08-01
DE4002836C2 (en) 1998-08-27
GB2227662A (en) 1990-08-08
FR2642311A1 (en) 1990-08-03

Similar Documents

Publication Publication Date Title
AU1022795A (en) Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
AU5495090A (en) Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
GB9002016D0 (en) Hmg coa reductase inhibitor and method for lowering serum cholesterol
IL112593A0 (en) Methods for inhibiting bone loss and lowering serum cholesterol
AU3681495A (en) Automated gaming table tracking system and method therefor
EP0508665A3 (en) Use of ace inhibitors for lowering serum cholesterol
AU6084686A (en) Novel hmg-coa reductase inhibitors
HU9402962D0 (en) Methods for lowering serum cholesterol
AU6205990A (en) Cold-rolled steel sheet for deep drawings and method of producing the same
AU619968B2 (en) Novel method and compounds
ZA899446B (en) Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination
GB2253225B (en) Steel utility structure and method for assembly thereof
EP0461548A3 (en) Method for preventing a second heart attack employing and hmg coa reductase inhibitor
AU635087B2 (en) Cholesterol ester hydrolase inhibitors
EP0415488A3 (en) 7-substituted hmg-coa reductase inhibitors
EP0608117A3 (en) Antibodies for mevalonic acid and methods for determination of mevalonic acid.
AU9642198A (en) Method and apparatus for determining the relative height of two targets
GB9002018D0 (en) Squalene synthetase inhibitor and method for lowering serum cholesterol
AU8160587A (en) Steel strip or sheet for di cans and production method thereof
AU3107693A (en) Method and reagents for determining the presence of giardia lamblia
PL337343A1 (en) Method of obtaining drugs comprising inhibitors of hmg coa reductase
EP0468974A4 (en) Novel hmg-coa reductase inhibitors
IE882653L (en) HMG CoA REDUCTASE INHIBITORS
IE862071L (en) HMG CoA REDUCTASE INHIBITORS
PL309939A1 (en) Method of detecting the factor of high cataract occurrence risk and set of reagents therefor

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20050130